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Abstract Human pluripotent stem cell-derived cardiomyo-
cytes (hPSC-CM) are being investigated as a new source of
cardiac cells for drug safety assessment. We developed a
novel scalable high content microscopy-based method for
the detection of cell death in hPSC-CM that can serve for
future predictive in vitro cardio-toxicological screens. Using
rat neonatal ventricular cardiomyocytes (RVNC) or hPSC-
CM, assays for nuclear remodelling, mitochondrial status,
apoptosis and necrosis were designed using a combination
of fluorescent dyes and antibodies on an automated micros-
copy platform. This allowed the observation of a
chelerythrine-induced concentration-dependent apoptosis
to necrosis switch and time-dependent progression of early
apoptotic cells towards a necrotic-like phenotype. Suscepti-
bility of hPSC-CM to chelerythrine-stimulated apoptosis
varied with time after differentiation, but at most time
points, hPSC-CM were more resistant than RVNC. This
simple and scalable humanized high-content assay generates
accurate cardiotoxicity profiles that can serve as a base for
further assessment of cardioprotective strategies and drug
safety.
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Introduction
Differentiation protocols for production of cardiomyocytes
from human embryonic or induced pluripotent stem cells
(hESC, hiPSC) are now robust, with staged application of
growth factors in a monolayer system as an alternative to
embryoid body methodology. It is possible to purchase these
cardiomyocytes (hESC-CM, hiPSC-CM) from commercial
sources, some with purities increased to more than 95 % by
genetic selection. This has led to their increasing adoption
by the pharmaceutical industry for drug discovery or toxi-
cology testing with hopes that this humanised platform will
improve predictive capabilities, since cardiotoxicity is one
of the most common causes for attrition of both cardiac and
non-cardiac drugs. There has also been uptake from aca-
demic researchers seeking an alternative to the standard rat/
mouse primary adult or neonatal cells. A further advantage
is the possibility to scale-up cell production and therefore
increase assay throughput using platforms which can then
be directly related or transferred to industry contexts. The plans
in progress by both academic centres and industry worldwide
to generate hiPSC lines from patients with known mutations
are set to create an enormous resource for the researcher, which
is likely to increase interest further. There have been striking
successes in modelling the ion channel mutations in various
clinical syndromes, with several long QT and other models
described [13, 17, 19, 23]. The hiPSC-CM from these patients
show not only the prolongation of action potential duration,
observable despite the theoretical concern about mixed atrial/
ventricular/nodal populations, but emergent characteristics
such as afterdepolarisations and arrhythmias. Most recently,
hiPSC-CM from patients with a troponin mutation were found
to display βAR changes normally associated with acquired
heart failure, in addition to sarcomeric changes, and to be
rescued by beta-blockers or SERCA2a gene therapy [30].
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For other processes including those involving complex
signal transduction cascades, such as hypertrophy, prolifer-
ation and cell death, it has not been so clear whether the
immature phenotype of pluripotent stem cell-derived cardi-
omyocytes will adequately model the terminally differenti-
ated primary ventricular myocyte. Efforts are now underway
to understand the characteristics of these changes in the
pluripotent stem cell-derived cardiomyocytes and whether
they utilise the authentic pathways observed in adult
myocardium. We have previously shown that hypertrophic
changes can be modelled in hESC-CM and are mediated by
canonical kinase signalling cascades [5]. In this paper, we
describe a similar strategy to study cell death in hESC-CM
and hiPSC-CM (together termed hPSC-CM), with direct
comparisons to rat neonatal ventricular cardiomyocyte
(RNVC) preparation. Rodent neonatal cardiomyocyte prep-
arations are presently the most widely used for investigation
of longer-term cardiac signalling because their ability to
survive in culture and to be manipulated genetically is
favourable compared to the adult ventricular myocyte. How-
ever, as well as having the advantage of a human genotype,
hPSC-CM remain stable in culture for considerably longer
still (for more than a year) and are equal or superior in
transfection efficiency to rodent neonatal cells. To take
advantage of the scale-up possibilities, we have used a high
content microscopy platform and optimised the assays to
create a robust readout for early and late apoptosis and
necrosis. This will provide a basis for studies of cardiotoxicity
and protection, with a direct applicability in drug discovery
and toxicology.
Methods
Cell Culture and Drug Treatment
Human ESC-CM were produced from the H7 hESC line
(WiCell Inc). Cells were grown in the undifferentiated state
on Matrigel (BD Biosciences) in mouse embryonic fibro-
blast conditioned medium, supplemented with 8 ng/ml of
recombinant human FGF-2 (R&D Systems). Cardiac differ-
entiation was performed using dense monolayers of hESC
treated with 100 ng/ml Activin-A for 24 h and 10 ng/ml
BMP-4 for 4 days in serum-free media, according to a
previously described protocol [12]. Following induction
with the growth factors, cultures were fed every other day
with RPMI with 2 % B27. Spontaneously beating areas
comprising sarcomeric myosin heavy chain- (MHC-) posi-
tive cells typically appeared after 15 days. Cardiomyocytes
were isolated using trypsin for 3 to 5 min and collagenase
IV (200 U/ml) for another 10 min. Clusters enriched in
cardiomyocytes were triturated with a micro-pipette, and
single cells were plated onto gelatinized 96 well plates.
Human iPSC-CM were purchased from Cellular Dynamics
International. These hiPSC-CM express mRFP and blastici-
din resistance under the αMHC promoter and are purified
before shipping (typically 95 % pure cardiomyocyte cul-
tures). RNVC were isolated as described elsewhere [18].
Human ESC-CM, hiPSC-CM and RNVC were plated at
50,000 cells/cm2. Three days post-isolation or recovery,
cells were treated with doxorubicin for 24 h or chelerythrine
for 1.5 h in RPMI+B27 media.
Live Staining and Immunochemistry
Live staining was performed in pure cardiomyocyte popu-
lations (i.e. RNVC and hiPSC-CM). Following drug treat-
ment, cells were incubated with Vybrant® FAM caspases 3
and 7 (Invitrogen) for 1 h and stained with TMRM, ToPRO-
3 and Hoechst 33342 (all Invitrogen) for 10 min. After
washing with PBS and replacement with fresh media,
stained cultures were placed in the Cellomics chamber at
37 °C/5 % CO2 and scanned. Alternatively, cardiomyocytes
including hESC-CM were stained with BOBO-1 and
Hoechst 33342 for 10 min prior to fixation with 4 % para-
formaldehyde. Following permeabilization with 0.2 %
Triton-X, cells were immunostained with polyclonal rabbit
anti-caspase 3 (Abcam, 1:500) and monoclonal mouse anti-
myosin heavy chain α/β (MHC α/β, clone 3–48, Abcam,
1:200) and anti-mouse Alexa 546 and anti-rabbit Alexa 647
(Invitrogen). Primary antibodies were detected with Alexa
546 and Alexa 647-conjugated secondary antibodies
(1:400).
Automated High Content Microscopy and Analysis
Images were acquired on ArrayScan™ VTi automated mi-
croscopy and image analysis system (Cellomics Inc., Pitts-
burgh, PA, USA) with ×10 objective suitable for filter sets.
Cells were identified with Hoechst fluorescence that defined
the nuclear area. Fluorescence intensities for the other chan-
nels were measured exclusively in the nucleus for Hoechst,
ToPRO-3 and BOBO-1, in the perinuclear area for TMRM
and MHC and in both cellular compartments for capsase-3
and caspase 3 and 7 substrate. Using modified SpotDetector
Bioapplication, only high fluorescence intensities were
detected and subsequent areas measured. In order to reduce
false positive due to small but bright autofluorescent par-
ticles or to background noise, we used the spotdetection tool
that recognizes contiguous pixels with high intensity, and
we discarded spots with smaller size. Cardiomyocytes were
identified using anti-MHC antibody. The fluorescence in-
tensity threshold discriminating cardiomyocytes and non-
cardiomyocytes was set manually in each experiment. In
mixed cultures of hESC-CM, data were collected only in
MHC positive cells. For caspases, a significant basal level in
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healthy cells complicated the analysis, and the method of
thresholding is described further in the “Results” section.
For other markers, discrimination between live and dead
cells was not based on a predetermined fluorescence inten-
sity because slight variation in quality of the staining or in
culture conditions (cell density) makes the use of a fixed
threshold inappropriate across experiments. Instead, we as-
sumed that the rate of cell death in control conditions
resulting from normal cell turnover is reasonably consistent.
Supported by thorough image observations and data from
others [11, 26], we made the assumption that 5 % of control
cells were either dead or in the process of dying. To set the
threshold above zero also gave the possibility for protective
effects to be detected under control conditions. Nuclear
shape (using numeric descriptors of shape complexity
ObjectShapeP2A) is an index based on the ratio of the
length and the width. Healthy cells are typically circular or
slightly elongated with a small nuclear shape index whereas
dying cells that undergo nuclear fragmentation may not only
be bigger (high Hoechst area) but may exhibit altered nu-
clear shape. For TMRM, active extrusion of the dye occurs
in healthy cells, and these living TMRM negative cells
confound with mitochondrial-compromised cells [9]. We
made the assumption that increase in the TMRM negative
population in treated cells was exclusively due to increase in
mitochondrial dysfunction and not to increased extrusion of
the fluorescent dye. For (1) a given individual parameter, (2)
different composite categories (e.g. late apoptosis) or (3)
total cell death the results are expressed as an index, calcu-
lated as: (% positive−threshold)/(100 %− threshold).
Statistics
Results are expressed as mean±SEM. Paired or unpaired t
tests or one-way ANOVA were used as appropriate. Differ-
ences at the level of P<0.05 were considered statistically
significant.
Results
Early events in the apoptotic pathway include loss of mito-
chondrial membrane potential and activation of caspases,
followed by changes in cell shape with membrane blebbing
and detachment, then later events such as nuclear remodel-
ling and final loss of sarcolemmal integrity [29]. We will
describe the markers used for these events and their optimi-
sation for the Cellomics Arrayscan™ high content screening
platform. Examples from neonatal and hESC or hiPSC-
derived cardiomyocytes are given for the optimisation steps,
and a direct comparison of sensitivity of the different cell
types to cell stressor chelerythrine is made under the chosen
conditions.
Mitochondrial Membrane Potential
Dissipation of the mitochondrial membrane potential (mΔψ)
initiates cell death in cardiomyocytes [16]. During apopto-
sis, mitochondrial outer membrane permeabilisation
(MOMP) is necessarily for apoptosome formation and thus
precedes effector caspase activation (although MOMP-
independent caspase 3 activation has also been described
[7]). We used the lipophilic cationic potentiometric dye
tetramethylrhodamine, methyl ester (TMRM) as a sensor
of mΔψ for live cells. Neonatal RVNC stained with TMRM
exhibit bi-modal fluorescence intensity distribution with a
large population of low TMRM staining in control (Fig. 1).
In addition to the small subset of apoptotic and necrotic cells
that are TMRM negative, active extrusion of the dye
through drug-resistance pump can explain the large number
of cells with low TMRM [9]. Treatment with the apoptosis/
necrosis inducer chelerythrine (100 μM) induced complete



























Fig. 1 Mitochondrial membrane potential collapse during chelerythrine-
induced cell death in rat neonatal ventricular myocytes. Rat neonatal
ventricular myocytes were exposed to chelerythrine (100 μM) in order
to induce maximal cell damage and complete loss of the mitochondrial
membrane potential. a In control cultures (left panel), most cells were
positive for TMRM (red); nuclei were identified by DAPI (blue). In
chelerythrine-treated myocytes (right panel), the TMRM signal disap-
peared and the proportion of permeable cells (BOBO-1, green) was
increased. b An example experiment (2,000 cells) showing the distribu-
tion of fluorescence intensity of TMRM in cells in the presence and
without chelerythrine. In chelerythrine-treated cells, where mitochondrial
membrane potential is lost, the intensity graph does not overlap with low
TMRM peak in control
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loss of TMRM signal in both low and high intensity cells
(Fig. 1), and this was complete after 160-min exposure.
Live cell dyes such as TMRM work well for pure
populations such as RNVC or genetically purified stem
cell-derived cardiomyocytes (such as the CDI hiPSC-
CM) but are leached during fixation. For the mixed
populations obtained from most differentiation proce-
dures, the use of reporters such as Mitotracker (which
is retained during processing) and co-staining with a
cardiac marker such as troponin I (TnI) or αMHC is
required to localise signal to cardiomyocytes. Supple-
mentary figure 1 shows the algorithm for cardiomyocyte
detection on the Cellomics Arrayscan platform. This
identifies cells from nuclear staining and quantifies
MHC staining intensity in a perinuclear ring. Most
nuclei are discreet, but there are small numbers where
more than one nucleus appears to be captured in a
circle. These can be fragments, as discussed in the cell
death section. They can also be dividing cells or true
binucleated cardiomyocytes (which is the normal adult
form). These are counted as single cells, and we esti-
mate an event rate of <20 % [5].
Activation of Effector Caspases
Activation of effector caspases (caspases 3, 6 and 7) is key
in the dismantling of the cell structure and machinery during
apoptosis [32]. Mitochondrial or receptor-mediated apopto-
sis both induce a cascade of caspase activation that con-
verges ultimately to the conversion of the pro-caspase 3 into
proteolytically active caspase 3. Assessment of caspase 3
activity can be performed by measurement of caspase 3 (and
caspase 7)-mediated degradation of specific fluorescent sub-
strate. Alternatively, anti-active caspase 3 antibody conju-
gated with a secondary antibody gives a measure of active
caspase 3 content in the cell at the time of fixation. Stable
control hESC-CM stained with anti-caspase 3 antibody
show significant fluorescence, mostly localized in the nu-
cleus, seen as sub-lethal levels of active caspase 3. Higher
levels of anti-caspase 3, localised in the nuclear and peri-
nuclear areas, were found in cells that underwent morpho-
logical changes typical of apoptosis such as cell shrinking
and the start of detachment (Fig. 2a). In a time course
experiment using chelerythrine, active caspase 3 increased
rapidly with concomitant decrease in hESC-CM number in



























































Fig. 2 Activation of caspase 3 in cardiomyocytes. a Human ESC-CM
are identified by immunostaining in fixed cultures, using anti-MHC
antibody (green) as a cardiac-specific marker. Active caspase 3 (red) is
most visible in the nuclear and perinuclear regions of the apoptotic
cells. Activation of caspases is typically accompanied by cell shrinkage
and detachment (solid and dotted white arrows, respectively). b Acti-
vation of caspase 3 and change in cell number in hESC-CM treated
with chelerythrine. Human ESC-CM were exposed to 10 μM cheler-
ythrine, and apoptosis index was measured at different time points.
Increase in apoptosis is accompanied with a dramatic reduction in cell
number due to cell detachment (n06 from one experiment, 2,000 cells
per well). Apoptosis index was calculated as: (% positive−threshold)/
(100 %− threshold). c hESC-CM double-stained for caspase 3 and
MHC; graph shows data from 5,270 control and 1,110 chelerythrine-
treated cells. d Fold changes between control and chelerythrine-treated
values using either unthresholded results (all) or the values remaining
after removing those below the threshold (thresholded)
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the culture (Fig. 2b). Active caspase 3 is present in hESC-
CM at a significant level (Fig. 2c), but chelerythrine treat-
ment produces a bimodal population intensity value distri-
bution (note the logarithmic scale). Using a threshold value
derived from normal populations increased the discrimina-
tion between conditions (Fig. 2c, d). Comparison of abso-
lute values from the whole population gives a modest fold-
induction (×1.4), but thresholding at mean±1.5× SD of
control gives better discrimination, with a 9.8-fold differ-
ence from control. Calculating the Z′ of this assay with this
thresholding gives an acceptable value of 0.81. Simulations
of other threshold values showed that a cutoff point exclud-
ing all control cells gives a maximum Z′ of 0.85, which is
similarly excellent but would exclude many caspase-high
cells in the second population and potentially limit detection
when apoptotic changes were small.
Relation Between Mitochondrial Membrane Potential
and Caspase Activation
Co-staining of hiPSC-CM with TMRM and caspase 3 and 7
substrate gave a different cell death profile after exposure to
10 μM chelerythrine or 10 μM doxorubicin. Chelerythrine
induced strong mitochondrial dysfunction whereas doxoru-
bicin did not. A high proportion (66±7.5 %) of apoptotic
cells (caspase 3 and 7 positive cells) underwent loss in
TMRM signal in chelerythrine treated cells. On the other
hand, only 4±0.8 % of hiPSC-CM were both caspase pos-
itive and TMRM negative when treated with doxorubicin
suggesting mitochondrial-independent activation of cas-
pases 3 and 7 (doxorubicin vs. chelerythrine p<0.001, n0
22 and n012, respectively). Therefore, apoptotic cells were
characterized according to their mitochondrial status: apo-
ptosis with MOMP and apoptosis without MOMP.
Cell Membrane Permeability
At the later stage of apoptosis or following traumatic cell
damage leading to necrosis, cells are no longer able to
maintain the integrity of their membrane. This results in
solute equilibrium between the intracellular and extracellu-
lar milieu, arrest in metabolic activity and thus characterizes
the final stage in the cell death process [33]. Impermeant
dyes such as commercialized cyanin dimer or propidium
iodine are able to enter dead cells and exhibit strong fluo-
rescence when bound to nucleic acids. Here, because of
fluorescence channel availability or requirement for further
fixation steps, we used different cyanine dimer nucleic acid
dyes such as BOBO-1 and ToPRO-3. These dyes differ in
their light emission wavelength but have similar function
and so were used interchangeably. Cells treated with doxo-
rubicin for 24 h and stained with BOBO-1 showed, as
expected, a bimodal distribution in nuclear average intensity
(Fig. 3a). Note also the clear separation between BOBO-1
positive cells and those with high TMRM signal (Fig. 3b).
Nuclear Events
Change in nuclear morphology is a hallmark of the final stage
in cell death. In apoptosis, these include chromatin condensa-
tion, nuclear fragmentation and DNA degradation. In our
assay, we recorded nuclear events as additional toxicity read-
outs regardless of the cell death pathway involved. Extreme
nuclear sizes discriminated chromatin condensation
(pyknosis) and nuclear fragmentation (karyorrhexis), although
the potential for a fragmented nucleus to be read by the high
content screening as an enlarged one required care in the
analysis. Terminally apoptotic cells, which are expected to
undergo nuclear remodelling due to the action of nuclear
proteases, also allow the entry of the impermeant dye
ToPRO-3 due to increase membrane permeability. Nuclear
characteristics of ToPRO-3 positive cells differ clearly from
ToPRO-3 negative cells (Fig. 3c). Dead cells have either
smaller or bigger nucleus size than control because of con-
densed or fragmented nuclei respectively, or display the other
changes shown in Fig. 3c. Hoechst intensity distribution is
commonly used in cytometry and high content assays for cell
cycle analysis. In cytometry studies, there may be a population
of cells below the G1/0 or 2 N peak with lower Hoechst
intensity seen as an apoptotic population with degraded
DNA [1]. Conversely, facilitated penetration of Hoechst in
terminal cells results in increased Hoechst nuclear intensity
(cell membrane permeability (CMP)/Hoechst readout). Here,
dead cells in control conditions exhibited nuclei with higher
Hoechst intensity but not with lower intensity (Fig. 3c, d).
This suggests that apoptosis-related DNA degradation does
not naturally occur during normal cell turnover in culture. In
contrast, DNA degradation is the most important nuclear
event in doxorubicin-induced cell apoptosis (see below).
Late Apoptosis Versus Necrosis
Whether a cell undergoes apoptosis with activation of cas-
pases or undergoes a less regulated death like necrosis
depends largely on the drug action and the drug concentra-
tion. Chelerythrine is known to induce apoptosis at 10 μM
and necrosis at higher concentration in RNVC [34]. We
confirmed this concentration effect in RNVC using apopto-
sis as defined before and necrosis as CMP positive cells
within the caspase 3 negative population (Fig. 4a). Finally,
we confirmed the progression of apoptotic cells towards a
necrotic-like phenotype in RNVC exposed to prolonged
treatment with 10 μM chelerythrine. A majority of apoptotic
cells were caspase 3 positive cells without CMP during the
90 first minutes whereas caspase 3+/CMP+ cells represented
50 and 95 % of the apoptotic population at 120 and 240 min
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of chelerythrine exposure, respectively (Fig. 4b). Therefore,
we created early and late stage apoptosis categories to
characterise the progression of cardiomyocytes towards the
apoptotic process based on their CMP and caspase 3 status
also for doxorubicin, please see Fig. 5.
Overall Assessment of Death Profiles
Individual (e.g. MOMP) and composite (e.g. late apoptosis)
measures were ranked by variability both under control
conditions and after challenge with 10 μM doxorubicin.
Cell number was clearly variable simply because of differ-
ences in plating, but other parameters are expressed as a
proportion of cells remaining. Individual parameters are
more variable than composite and, in general, show less
significant changes on doxorubicin treatment: This supports
the use of composite measures. Further, a “fingerprint”
representation of the cell death profile can be done for
different stimuli, cell types and conditions. In Fig. 6, we
show an example radar graph for doxorubicin and cheler-
ythrine in which the different aspects of apoptosis and
necrosis are represented.
Comparison of Cell Death in RNVC and hESC-CM
Chelerythrine induced caspase 3 activation, nuclear remod-
elling, cell loss and moderate necrosis. Together this con-
firms a pro-apoptotic effect of chelerythrine in both
cardiomyocyte models. However, comparison of the cell
death indices revealed a significant quantitative difference
between hESC-CM and RNVC in term of caspase 3 activa-
tion (apoptosis index011±2.4 and 31.9±4.6, respectively,
p00.0001), a difference in cell loss (36.8±7.5 and 62.6±






































































Fig. 3 Nuclear events during cell death in human induced pluripotent
stem cell-derived cardiomyocytes. a Bimodal distribution of nuclear
BOBO-1 fluorescence intensity. b Healthy cells show intact mitochon-
dria with TMRM positivity whereas dead cells are exclusively BOBO-
1-positive and TMRM-negative. c Nuclear remodelling in ToPRO-3-
negative and -positive hiPSC-CM under control conditions. The subset
of dead cardiomyocytes in control were assessed for their nuclear size,
DNA content, membrane permeabilisation (CMP, high Hoechst inten-
sity) and nuclear fragmentation (n05 preparations). d Rat neonatal
ventricular myocytes exposed to chelerythrine at t0 and t180min
(repeated images from the same field). Nuclei are large and round
shaped before the drug induces toxic effects, whereas nuclei are rather
small, with condensed chromatin after 3 h of exposure (yellow arrows).
Alternatively, cells can detach from the substrate, resulting in reduction
in cell number (blue arrow). Note that pyknotic nuclei are usually
brighter as a consequence of concomitant cell membrane permeabilisa-
tion (CMP/Hoechst) or extreme condensation of the chromatin
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nuclear remodelling (p00.08 and p00.39, respectively)
(Fig. 7). These data suggest that hESC-CM are more resistant
than RNVC following chelerythrine treatment. Importantly,
there was no switch from apoptosis to necrosis in hESC-CM
as shown by the low and similar necrotic index in both species.
Cell Death in hESC-CM with Time in Culture
We further investigated the effect of chelerythrine in hESC-
CM at different times after differentiation to cardiomyocytes
from 38 days, which represents an early stage hESC-CM in
maturation, to 155 days, considered as a late stage [28]. Our
data suggest that the sensitivity of hESC-CM to chelerythr-
ine differs strongly according to the stage of differentiation
(Fig. 5). Early hESC-CM were resistant to apoptosis but a
rapid change occurred during the intermediate stage
(day 65) where hESC-CM seemed almost as sensitive to
chelerythrine as the RNVC. From the intermediate stage to
the late stage of differentiation, hESC-CM developed pro-
gressive resistance to chelerythrine but were still more sen-
sitive than the early stage.
Discussion
High content screening (HCS) is now a central paradigm for
drug discovery, including the investigation of off-targets
effects such as cell toxicity. In addition to its promising
use for industry, automated microscopy in micro-plate for-
mat has several advantages over other methods to interro-
gate hPSC-CM cell death. Firstly, the generation of hPSC-
CM remains relatively expensive in comparison with im-
mortalized cell lines so that the use of smaller cell numbers
is an advantage. Secondly, although differentiation of hPSC
can be directed into cardiovascular lineages, a proportion of
the differentiated derivatives will not be of the cardiomyo-
cyte phenotype, which excludes any method based on cell
lysates. Even if mechanical and genetic purification meth-
ods are available and have been shown to be successful [2,
9], they are still technically challenging. There is also the
theoretical concern that selection methods, such as strong
antibiotic treatment (for cells with antibiotic resistance
genes) or FACS sorting, have the potential to favour a
subpopulation of hardy cells over those which are more
fragile. This could bias the sensitivity of cell death
responses in general. When mixed cultures must be used,
immunochemical methods to identify hPSC-CM by cardiac-
specific antibodies can be combined with other markers of
the cell death process. Here we have described both live
assays in pure cultures of cardiomyocytes and assays with
fixed cells in mixed cultures.
The onset of the cell death program ranges from few
seconds to several hours [24], whether the stimulus acts
through the activation of pro-apoptotic genes or induces
direct damage to organelles. Apart from the typical morpho-
logical changes specific to the different forms of cell death,
there is no universal biochemical marker that identifies
clearly an apoptotic or a necrotic cell. With a range of
markers for mitochondrial membrane potential, caspase ac-
tivation, cell loss, nuclear remodelling and cell membrane
permeabilisation, we have defined the path through early
and late apoptosis to necrosis.
Early events in the apoptosis program involve the mito-
chondrial translocation of pro-death molecules into the cytosol
and the nucleus, leading to effector caspase activation and
DNA damage, respectively [27]. The dissipation of the mito-
chondrial membrane potential is seen as central in the release
of pro-death factors although release of cytochrome-c has
been observed in the absence of mitochondrial membrane
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Fig. 4 Concentration and time-dependent effects of chelerythrine in
rat neonatal ventricular myocytes. a Chelerythrine dose-dependent
induction of apoptosis and necrosis in RNVC. Stacked bar graph
shows that apoptosis peaked at a concentration of 10 μM (90 min)
whereas necrosis predominated at higher chelerythrine concentrations.
n06 from 1 experiment, 2,000 cells analysed per well. b Caspase-3
activation is followed by secondary necrosis in RNVC. Cells were
exposed to chelerythrine (10 μM) at different times and stained for
CMP marker BOBO-1 and apoptotic marker anti-caspase 3. Stacked
bar graph shows early apoptosis (caspase 3-positive/BOBO-1-negative
cells) predominates during the first minutes of exposure with the drug
whereas late apoptosis (caspase 3-positive/BOBO-1-positive cells)
characterized the apoptotic population at a later time point (240 min).
Cell death index was calculated as: (% positive− threshold)/(100 %−
threshold)
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potential collapse [15]. The participation of mitochondrial
dysfunction in cardiomyocyte apoptosis may have critical
implications such as the depletion of the intracellular ATP
stores, which orchestrates the apoptosis to necrosis switch.
Here we show that hiPSC-CM exposed to doxorubicin can
undergo effector caspase activation in the absence of
mitochondrial membrane potential dissipation, which may
have important implications for future cardioprotective strat-
egies in cancer chemotherapies. However, our system does
not allow investigation of other aspects of mitochondrial
dysfunction, such as mitochondrial fragmentation, that may
also occur during doxorubicin treatment [22].
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Fig. 5 Individual and
composite readouts to
characterize cardiotoxicity
profiles. Median, upper and
lower quartiles and values are
shown in a control and b
doxorubicin-treated hiPSC-CM,
with n 0 wells in brackets.
Parameters were ranked by
interquartile range of control
populations. CMP cell mem-
brane permeability, Hs Hoechst,
MOMP mitochondrial outer
membrane permeabilisation,
apop apoptosis, casp caspase.
*P<0.05;**P<0.01; ***P<
0.001 versus respective controls
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The activation of caspase 3 is considered as an interme-
diate event in the cell death process as well as the onset of
the irreversible dismantling of the cell machinery [4].
Importantly, necrotic cell death does not involve caspase
proteolysis, and thus, the activation of caspases is a good
candidate for the discrimination between the two forms of
cell death [27]. However, active caspases, in particular cas-
pase 3, can be involved in other processes than apoptosis,
including cell division [8] and differentiation of tumour cells
and embryonic stem cells [6, 14, 20, 31]. Furthermore,
crosstalk between differentiation and death pathways was
investigated [3], and caspase 3 has been demonstrated in-
dispensable for normal cardiovascular formation in mouse
[21]. This last point is particularly important as hESC-CM
are immature cardiomyocytes freshly derived from hESC
and may be in the process of phenotypic maturation. It is
possible that the significant basal level of caspase 3 in
hESC-CM that we observed is a characteristic of incom-
pletely matured hESC-CM. However, the activation of cas-
pase 3 is considered, to date, as the most reliable marker to
detect apoptosis [4, 27]. Here we showed that active caspase
3-associated fluorescence intensity increased after exposure
to 10 μM chelerythrine in hESC-CM and RNVC and that
this was sufficiently differentiated from basal levels to give
an assay with an acceptable Z′ score. Also, the observation
of cells by fluorescent microscopy revealed that high level
of caspase 3 fluorescence was associated with morphologi-
cal changes typical of apoptosis (membrane blebbing, lifting
and shrinkage). The activation of caspase 3 in either RNVC
or hESC-CM was followed by a dramatic loss in cell num-
ber, as a result of cell detachment, and was accompanied by
nuclear remodelling, mainly seen as chromatin condensa-
tion. Together, our data confirm that activation of caspase 3
as assessed by immunocytochemical methods is a good
marker to distinguish apoptosis and necrosis in both primary
and pluripotent stem cell-derived cardiomyocytes.
Cell detachment from the substrate, observed as cell loss,
was similarly an intermediate event. Interestingly, it was
neither correlated to the concentration of chelerythrine nor
to the necrotic index but was strongly correlated to the
apoptotic index. We showed that there was no overestima-
tion of the cell number resulting from possible nuclear
fragmentation but that apoptotic cells were more prone to
detachment than the necrotic cells. Two hundred and eighty
targets of caspase 3 have been identified so far, including
structural proteins that maintain cell morphology and cell
adhesion [4]. Proteolysis of cadherin and integrins by acti-
vated caspases can facilitate membrane detachment and
subsequent cell loss [4]. In both apoptosis and necrosis,
elevated intracellular calcium activates proteases such as
calpain and lysosomal cathepsins [25], but the extent of
the cytoskeleton and adhesion protein remodelling is likely
to be more severe in apoptosis due to the additional proteo-
lytic action of the caspase 3. However, while biologically
consistent, cell loss can be a limiting factor for automated
assays because of the inability to characterise the lost car-

























Fig. 6 Radar chart showing multivariate chelerythrine and
doxorubicin-induced cell death profiles in hiPSC-CM. Both drugs
induced cardiomyocyte death but with clearly different toxicity signa-
tures. Chelerythrine induced mitochondria dysfunction (MOMP), cell
shape remodelling, chromatin condensation and moderate apoptosis
and necrosis. Doxorubicin was a strong inducer of DNA degradation,
early apoptosis (caspase 3 and 7 substrate without cell membrane
permeabilization) with intact mitochondrial membrane potential. Axis
shows cell death index, with zero representing the control. Doxorubi-
cin: n022, four experiments; chelerythrine n012, two experiments
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Cell permeabilisation was a late event in the cell death
process. Depending on the secondary antibody fluorescence
wavelength forMHC and caspase 3 detection, different imper-
meant dyes can be used to assess sarcolemmal integrity, such
as BOBO-1 (green pseudocolour), propidium iodide (red) and
ToPRO-1 (far red). BOBO-1, for example, discriminates
clearly live and dead cells, giving a bi-modal distribution of
intensity in non-fixed culture. We found that the different
plasma membrane impermeant dyes correlate very well be-
tween each other (not shown) and thus can be alternatively
used according to the experimental design. BOBO-1 and
caspase 3 function as a couple to discriminate apoptosis from
necrosis and to determine the stage in the progression of
apoptosis. We created categories such as early apoptosis (high
caspase/low BOBO-1), late apoptosis (high caspase/high
BOBO-1) and necrosis (low caspase 3/high BOBO-1) and
showed that these categories are relevant to the time scale of
apoptosis and to the dose-dependent switch between
programmed cell death and traumatic cell death using cheler-
ythrine. Changes in nuclear morphology provided added in-
formation about the late stage of cell death, with either
fragmentation or condensation of nuclei as well as alterations
in Hoechst staining intensity being associated with cell death
as determined by permeabilisation.
After using RNVC, hESC-CM or iPSC-CM to optimise the
assay conditions and define the progression of markers, we
performed a more explicit comparison between the primary
and stem cell-derived cardiomyocytes. We used the concentra-
tion and the exposure time of chelerythrine that induced the
maximal apoptotic effect in RNVC. Human ESC-CM showed
a similar profile, with the peak of caspase 3 activation being at
10 μM and apoptosis switching to necrosis at greater doses. In
both cell types, the effect started at 40 min and peaked at
90 min. However, at this maximal apoptotic concentration,
early hESC-CM were more resistant than rat RNVC in terms
of the apoptosis and cell loss. Importantly, we showed that this
resistance to apoptosis was not offset by an increase necrosis in
hESC-CM. Looking further, we saw that the sensitivity of
chelerythrine-induced apoptosis changed with the stage of
differentiation of hESC-CM. Early hESC-CM (day 38) show
very little sensitivity to chelerythrine, but a rapid change oc-
curred at the intermediate stage (day 65) where the sensitivity
was maximal (26.7±1.3) and similar to that of RNVC. Further
hESC-CM aging/maturation brought a decreased sensitivity to
chelerythrine as seen by the lower apoptosis index during the
late stage (days 94, 105 and 155). Chelerythrine is a benzo-
phenanthridine alkaloid commonly used in research as a potent
selective protein kinase C (PKC) inhibitor [10], but in some
studies, chelerythrine-induced apoptosis in rat neonatal cardi-
omyocytes was found to bemediated through the generation of
intracellular ROS rather than PKC inhibition [34]. Immature
cardiomyocytes are typically resistant to oxidative stress,
which would account for the initial insensitivity of the hESC-
CM to chelerythrine but makes the later re-development of
resistance more puzzling. It would be interesting to investigate
whether the peak of sensitivity to apoptosis in hESC-CM at the
intermediate stage of differentiation mimics the developmental
remodelling during morphogenesis of the embryonic heart,
which is largely dependent upon caspase 3 activity, at least in
animals [35]. Furthermore, this would be consistent with the
increased resistance of late hESC-CM because the myocytes
predisposed to undergo developmental-dependent apoptosis
during the intermediate stage would die, resulting in a positive
selection of resistant cardiomyocytes. Despite their conve-
nience in the HCS system, this resistant phenotype would
suggest that caution is needed when incorporating hPSC-CM
into assays to predict toxicity in the adult human heart.
In summary, a portfolio of markers defining the time course
and process of cell death can be used with either live or fixed
pluripotent stem cell-derived cardiomyocytes. The statistical
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Fig. 7 Chelerythrine induced a different cell death signature in hESC-
CM and in rat neonatal ventricular myocytes. a Cardiomyocytes were
exposed to 10 μM of chelerythrine for 90 min. Cell death index was
calculated as: (% positive−threshold)/(100 %− threshold). RNVC (left
bars) n011 from three experiments; hESC-CM (right bars) n021 from
five experiments. Student’s t test, *p<0.05, ***p<0.001 compared to
corresponding bar in the neonatal myocyte group. b Sensitivity to
chelerythrine-induced apoptosis in hESC-CM varies according to the
stage of differentiation. Apoptosis index is shown as mean±SEM in
hESC-CM. n03 for days 38 and 65; n06 for days 94, 104 and 155
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differences in mechanism between toxic agents and to pro-
duce a “fingerprint” that can be either cell type or stimulus-
specific. Composite end points such as late apoptosis or total
cell death showed reduced variability compared to individual
markers. Pluripotent stem cell-derived cardiomyocytes are
well suited to this system because of their robust cardiac
phenotype and stability in prolonged culture. For pharmaceu-
tical companies, they could replace the CHO and HEK cells
currently used for toxicity profiling. Although not replacing
animals directly, their cardiomyocyte phenotype would allow
a more sophisticated assessment of cardiotoxicity, as opposed
to general cell toxicity, and therefore potentially remove a
further tranche of unsuitable compounds before in vivo stud-
ies. For the researcher, the preparations most likely to be
replaced are the adult or neonatal rodent cardiomyocytes,
presently a mainstay for in vitro studies. The enthusiasm of
the field for exploration of the potential of iPSC-derived
cardiomyocytes is therefore justified, although the challenge
of their immature characteristics persists, and their predictive
power remains to be established. Their human origin will be
an overriding advantage, especially with the advent of an era
where a large number of genotype-specific iPSC lines will
soon become available to the cardiac researcher.
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